Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Sept. 23, 2024—Bio-Rad Laboratories has announced a partnership with Sysmex America in Bio-Rad’s Unity Next Peer QC software is now available with Sysmex CA-Series and CS-Series hemostasis systems for the United States.
Sept. 20, 2024—Novartis announced FDA approval of Kisqali (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of people with HR+/HER2- stage II and III early breast cancer at high risk of recurrence, including those with node-negative disease.
Sept. 18, 2024—The Digital Pathology Association (DPA) invites you to attend this year’s annual meeting, taking place Nov. 3–5 in Orlando, Fla.
Sept. 17, 2024—Qiagen is calling for a sharper focus on testing strategies to stop new cases of tuberculosis from further increasing and spreading in the United States.
Sept. 11, 2024—Randox now offers Olink dual-antibody recognition and proximity extension assay (PEA) technology, bringing the Olink Explore, Target, and Flex panels in-house to accelerate highly specific multiplex biomarker screening.
Sept. 10, 2024—Pillar Biosciences has entered into a strategic partnership with AstraZeneca to expand laboratory access to molecular testing using rapid next generation sequencing–based liquid biopsy tumor profiling panels for detecting genetic cancer variants.
Sept. 4, 2024—QuidelOrtho has received FDA 510(k) clearance for its Vitros syphilis assay, intended for the qualitative determination of total (IgG and IgM) antibodies to Treponema pallidum-specific antigens in human serum and plasma using the automated Vitros 3600, 5600, and XT 7600 systems.
Sept. 3, 2024—Maine Molecular Quality Controls has launched reference materials for the Cepheid Xpert PML-RARA assay.
Aug. 30, 2024—Qiagen has expanded its master collaboration agreement with AstraZeneca to develop and commercialize companion diagnostics for therapies being developed by AstraZeneca to address chronic diseases.
Aug. 29, 2024—Illumina announced Food and Drug Administration approval of its in vitro diagnostic TruSight Oncology Comprehensive test and its first two companion diagnostic indications.
